200 related articles for article (PubMed ID: 10100590)
1. Comparative brain tissue distribution of camptothecin and topotecan in the rat.
El-Gizawy SA; Hedaya MA
Cancer Chemother Pharmacol; 1999; 43(5):364-70. PubMed ID: 10100590
[TBL] [Abstract][Full Text] [Related]
2. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines.
Zamboni WC; Houghton PJ; Hulstein JL; Kirstein M; Walsh J; Cheshire PJ; Hanna SK; Danks MK; Stewart CF
Cancer Chemother Pharmacol; 1999; 43(4):269-76. PubMed ID: 10071976
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.
Scott DO; Bindra DS; Stella VJ
Pharm Res; 1993 Oct; 10(10):1451-7. PubMed ID: 8272406
[TBL] [Abstract][Full Text] [Related]
5. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
[TBL] [Abstract][Full Text] [Related]
6. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio.
Chen J; Hu RR; Yang XX; Gu W; Tian R; Gong F; Luo L; Fang F; Chen ZP; Cai BC
Cancer Chemother Pharmacol; 2013 Oct; 72(4):925-9. PubMed ID: 23934323
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
[TBL] [Abstract][Full Text] [Related]
11. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
[TBL] [Abstract][Full Text] [Related]
13. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
[TBL] [Abstract][Full Text] [Related]
14. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein.
Yao S; Petluru P; Parker A; Ding D; Chen X; Huang Q; Kochat H; Hausheer F
Cancer Chemother Pharmacol; 2015 Apr; 75(4):719-28. PubMed ID: 25634596
[TBL] [Abstract][Full Text] [Related]
17. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection.
Bai F; Kirstein MN; Hanna SK; Iacono LC; Johnston B; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Feb; 784(2):225-32. PubMed ID: 12505770
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic potential of camptothecin and topotecan.
Clements MK; Jones CB; Cumming M; Daoud SS
Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915
[TBL] [Abstract][Full Text] [Related]
19. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
[TBL] [Abstract][Full Text] [Related]
20. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF.
Leggas M; Zhuang Y; Welden J; Self Z; Waters CM; Stewart CF
J Pharm Sci; 2004 Sep; 93(9):2284-95. PubMed ID: 15295789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
